explore -WSS

explore

author：comprehensive 2025-08-12 08:26:01 - browse：7

Sammy Kimball for STAT

Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： R1 RCM gets $5.8 billion buyout offer from private equity firm

focus

WSS

Medicare inequities exacerbate Puerto Rico’s health disparities

Affordable Connectivity Program vital to health care, experts say

A solution to the after

Community Health Systems hospitals under DOJ investigation

I learned firsthand about improving diversity in clinical trials

Dario to buy mental health app maker Twill in cash and stock deal

focus

explore

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Stanford president faces new allegations over 1999 paper

DIEP, the 'gold standard' of breast reconstruction, is under threat

In utero gene editing: an explainer

Medicare details structure of new drug price negotiation program

In utero gene editing: an explainer

What does generative AI mean for health care? We asked experts

Why Congress must ban federal programs from using QALYs

Medical leaders decry Supreme Court decision on affirmative action

Alabama IVF ruling threatens families facing fatal genetic disease

hotspot

Divers poised to search for children washed away in Pennsylvania flash flood

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Why palliative psychiatry is worth discussing

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

New documents shed light on MD Anderson Cancer Institute feud

R1 RCM gets $5.8 billion buyout offer from private equity firm

hotspot

focus

focus

entertainment